🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, TRABECTEDIN

    Fondazione Telethon ETS

    recurrent ovarian cancer

    phase 2 small molecule active

    1 trial

  2. Calcio levofolinato Teva Generics 175 mg polvere per soluzione per infusione, BEVACIZUMAB , ZALTRAP 25 mg/ml concentrate for solution for infusion, Oxaliplatin 5 mg/ml concentrate for solution for infusion, Stivarga 40 mg film-coated tablets, FLUOROURACIL , FLUOROURACIL , Irinotecan Accord 20 mg/ml concentrato per soluzione per infusione, CAPECITABINE

    Fondazione Telethon ETS

    Patients with metastatic colorectal cancer (mCRC) RAS-mutant

    phase 2 small molecule active

    1 trial

  3. Calquence 100 mg film-coated tablets

    AstraZeneca

    mantle cell lymphoma (MCL)

    phase 2 small molecule active

    1 trial

  4. Calquence 100 mg film-coated tablets, ACALABRUTINIB

    Ningbo Cancer Hospital

    Disseminated large B-cell lymphoma

    phase 2 small molecule active

    1 trial

  5. Calquence 100 mg film-coated tablets, Calquence 100 mg hard capsules

    Lacuna Pharma Pty Ltd

    Waldenström Macroglobulinemia

    phase 2 small molecule active

    1 trial

  6. Calquence 100 mg film-coated tablets, Calquence 100 mg hard capsules

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory marginal zone lymphoma

    phase 2 small molecule active

    1 trial

  7. Calquence 100 mg hard capsules, Calquence 100 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  8. Calquence 100 mg hard capsules, Calquence 100 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Richter's Syndrome, Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  9. Calquence 100 mg hard capsules, IMBRUVICA 420 mg film-coated tablets, IMBRUVICA 140 mg hard capsules, IMBRUVICA 140 mg hard capsules, BRUKINSA 80 mg hard capsules, Lisaftoclax, Calquence 100 mg hard capsules, MabThera 500 mg concentrate for solution for infusion, Lisaftoclax, Lisaftoclax

    Lacuna Pharma Pty Ltd

    Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

    phase 2 small molecule active

    1 trial

  10. Camidanlumab Tesirine

    ADC Therapeutics SA

    Relapsed Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial

  11. Camrelizumab

    The First People's Hospital of Lianyungang

    Melanoma

    phase 2 small molecule active

    1 trial

  12. Camrelizumab

    The First People's Hospital of Lianyungang

    Lung Cancer, Nonsmall Cell

    phase 2 small molecule active

    1 trial

  13. Camrelizumab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  14. Camrelizumab

    The First People's Hospital of Lianyungang

    Lung Neoplasms

    phase 2 small molecule active

    1 trial

  15. Camrelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Adrenal Cortical Carcinoma

    phase 2 small molecule active

    1 trial

  16. Camrelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  17. Camrelizumab

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 2 small molecule active

    1 trial

  18. Camrelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  19. Camrelizumab

    The First People's Hospital of Lianyungang

    Locally Advanced or Metastatic Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  20. Camrelizumab

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  21. Camrelizumab Plus Apatinib

    Nanjing Zenshine Pharmaceuticals

    Unresectable Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  22. Camrelizumab and SBRT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 other active

    1 trial

  23. Camrelizumab plus apatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  24. Camrelizumab with vinorelbine and cisplatin

    The First People's Hospital of Lianyungang

    HER2-negative Breast Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources